| |
|
|
| |
|
|
| |
| |
hum-molgen: events in
bioscience and medicine |
|
| |
October, 04 2026 |
your calendar for events in genetics, biotechnology
and medicine |
|
| |
|
|
|
|
|
|
| |
advertisement |
|
search meetings |
|
recent postings |
|
|
|
|
| |
=> advertise at hum-molgen
|
|
|
|
| - |
As the biologics landscape becomes increasingly complex and therapeutic modalities grow more sophisticated, potency assay strategies are evolving from regulatory requirements into powerful tools that : Potency Assays for Modern Biologics: Expert Insights and Future Trends |
| - |
Artificial Intelligence (AI) is rapidly transforming biometrics functions across the clinical trial lifecycle, from protocol design and statistical analysis planning to programming, data standardizati: AI Governance in Clinical Trial Biometrics: A Practical Framework for Small-Mid Size Organization |
| - |
Early-phase clinical trials operate under compressed timelines, complex protocols, narrow eligibility criteria and limited patient populations, making even small delays disproportionately costly. For : Accelerate Biotech Patient Recruitment with Smarter Site Selection |
| - |
Executing clinical trials in complex glomerular diseases require moving beyond traditional functional involvement. As treatment paradigms and regulatory expectations for surrogate endpoints evolve, in: Navigating the Evolving Landscape of Glomerular Disease Clinical Trials |
| - |
As biopharmaceutical programs advance under increasingly compressed timelines, upstream development teams face pressure to deliver optimized, quality-targeted processes earlier. Early decisions still : Accelerate Upstream Process Development Using Hybrid Modeling |
| - |
Oncology innovation is accelerating across therapeutic modalities, precision medicine, biomarkers and artificial intelligence. But as scientific possibilities expand, the growing challenge for sponsor: Oncology Drug Development in 2026: From Scientific Innovation to Global Execution (Broadcast 2) |
| - |
Sterile drug product fill-finish is where years of development either pay off or unravel. Partnering with a CDMO that has isolator lines does not guarantee success. The difference lies in the depth of: Fill-Finish Success: From Isolator Qualification to GMP Production |
| - |
Enzyme replacement therapies have transformed the treatment landscape for many rare genetic and metabolic disorders by addressing enzyme deficiencies that drive disease progression. By supplying a fun: Enzyme Therapy Manufacturing: Preserving Activity Through Production |
| - |
Psychiatric drug development still leans on rating scales developed decades ago: subjective instruments that capture how a patient describes feeling but not what the brain is doing. In major depressiv: Can Objective Brain Measures Improve MDD Trial Decisions? |
| - |
Early-phase neuroscience trials have traditionally focused primarily on establishing safety and tolerability. From Alzheimer's disease to psychiatry, early development strategies can also generate mea: Lessons Learned in Neuroscience Drug Development: How Biomarker-based, Evidence-driven Decisions Enable Successful Outcomes |
 Get the latest news as RSS feed
|
|
| |
|
|
|
|
|
|
| |
news alert (free) |
|
write an announcement |
|
other resources |
|
| |
|
|
|
|
|
|
| |
To receive our regular news
alert (free - including summary of recent position postings) please register at our
bulletin board.
|
|
Please use our webform for direct postings after you have been set up your account.
By using this site you reach more than
8.000 news alert subscribers and 150.000 HUM-MOLGEN web users and
several mirror sites (e.g. Calender
of Events) in the US, China, Israel and France.
To further improve "hum-molgen: events in bioscience and
medicine" we have redesigned our database and web submission
form. The updated version enables the set up of accounts. By this
way advertisers are in the position to change postings and to submit
multiple postings more efficient. Please report potential problems
/ suggestions for further improvements to the www administrator Kai Garlipp (kai+www@garlipp.de).
|
|
HGMIS Calendar
of Genetic Meetings and Training
Calendar
LifeSciencesInfo.com
How to
Attend a Meeting by Dave Barry
|
|
|
|
|
|
|
|
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
WWW: Kai Garlipp,
Frank S.
Zollmann.
7.0 © 1995-2026 HUM-MOLGEN. All rights reserved.
Liability, Copyright and Imprint. |
|